Heteropolymers: a novel technology against blood-borne infections.
Heteropolymer (HP) technology is a novel cassette technology which is being developed for the treatment of infectious and autoimmune diseases. HPs are dual antibody conjugates, composed of a monoclonal antibody (mAb) directed against the complement receptor type 1 (CR1) on primate red blood cells (RBCs) chemically cross-linked to mAbs that recognize blood-borne antigens. Upon administration of an HP, the target is bound to its counterpart mAb in the HP and immobilized on an RBC by binding of the anti-CR1 mAb to CR1 in a complement-independent manner, forming an immune complex. When the RBC traverses the liver during circulation, the immune complex is recognized by fixed tissue macrophages, the CR1 molecule is cleaved and the HP-pathogen complex is phagocytosed and destroyed. Due to rapid binding and immobilization of the target by HPs, the anti-target mAb used in the HP need not be directed to a neutralizing epitope on the target organism. Studies in animal models have shown that HPs are effective in treating infectious diseases and autoimmune diseases such as systemic lupus erythematosus. HPs are advantageous over natural immune adherence or conventional mAb therapies due to their complement-independent mechanism, low therapeutic dose and lack of the need for neutralizing mAbs against the target.
Mohamed
Nehal
N
Elusys Therapeutics Inc, 25 Riverside Drive, Pine Brook, NJ 07058, USA.
Jones
Steven M
SM
Casey
Leslie S
LS
Pincus
Steven E
SE
Spitalny
George L
GL
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000941:Antigens / Q000276:immunology; D017848:Blood-Borne Pathogens; D003141:Communicable Diseases / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D051379:Mice; D011951:Receptors, Complement / Q000235:genetics / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000941:Antigens; D011951:Receptors, Complement